globe usa magnifying-glass checkbox g-plus rss youtube fb-round connect-with-us-in connect-with-us-twitter youtube2 facebook linkedin twitter
The website you have requested may contain information on products or uses of such products that are not approved in your country. For specific product and country information please contact Medinol


  • 5.4% target lesion failure at 12 months
  • 0.4% stent thrombosis at 24 months
  • 0% late stent thrombosis at 12 months
  • EluNIR was found non-inferior to Resolute in a broad, less selected ‘more comers’ population
TLF at 12 Months

Stent Thrombosis within 24 Months

Kandzari, David E. et al. Randomized comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stent in Patients with Coronary Artery Disease Circulation (2017) 136: 1304-1314

Watch Dr. David Kandzari as he reviews the EluNIR clinical program

Watch Dr. Alaide Chieffo as she reviews the 1 year outcomes of the BIONICS trial